Symposium 5: Metabolites and medication safety

E/Prof Geoff Tucker, Simcyp Ltd

Geoff is Emeritus Professor of Clinical Pharmacology at the University of Sheffield, UK; Ph.D (1967) from the University of London and an honorary D.Sc (2006) from the University of Uppsala. He has published widely in clinical and theoretical pharmacokinetics, pharmacogenetics, drug metabolism, drug-drug interactions and the pharmacology of drugs used in anaesthesia. Geoff is Chairman of the Board of Pharmaceutical Sciences of the International Pharmaceutical Federation (FIP), Fellow of the Royal College of Anaesthetists, the Royal College of Physicians Edinburgh), the Faculty of Pharmaceutical Medicine, Royal College of Physicians UK, the British Pharmacological Society and the British Toxicological Society. Founder of Simcyp Ltd, a spin-out company specialising in predictive pharmacokinetics.

Dr Kashyap Patel, Monash University

Dr Kashyap Patel is a Research Fellow at Monash University, Melbourne, Australia. He received his PhD from The University of Auckland (NZ) in 2010, where he developed a spatially-resolved pharmacokinetic/pharmacodynamic model for the hypoxia-activated anticancer prodrug PR-104. In 2010, Kashyap undertook a post-doctoral fellowship at the University of Queensland under the supervision of Professor Carl M. Kirkpatrick. During this tenure, he developed population pharmacokinetic/pharmacodynamic models for antifungal drugs and for a novel class of cardio-endocrine hormones. His current research focuses on modelling the effects of antimalarials, antimicrobials and drugs used in the treatment of sepsis.

Dr Michael Wiese, The University of South Australia

Dr Michael Wiese is a Senior Lecturer at the University of South Australia, School of Pharmacy, having worked as a clinical pharmacist for 10 years prior to receiving his PhD in 2007, upon which he took up his current position at the University of South Australia. He currently teaches into the second and third years of the Bachelor of Pharmacy program, and has research interest in the optimisation of conventional DMARDs in the treatment of Rheumatoid Arthritis via the use of pharmacogenomics and therapeutic drug monitoring, and in the underlying pathophysiology and diagnosis of drug allergies.

Craig Lindsley, Vanderbilt University, USA